A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

Neha Korde, Mattias Carlsten, Min Jung Lee, Alex Minter, Esther Tan, Mary Kwok, Elisabet Manasanch, Manisha Bhutani, Nishant Tageja, Mark Roschewski, Adriana Zingone, Rene Costello, Marcia Mulquin, Diamond Zuchlinski, Irina Maric, Katherine R. Calvo, Raul Braylan, Prashant Tembhare, Constance Yuan, Maryalice Stetler-StevensonJane Trepel, Richard Childs, Ola Landgren*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

110 Scopus citations
Original languageEnglish
Pages (from-to)e81-e83
JournalHaematologica
Volume99
Issue number6
DOIs
StatePublished - 1 Jun 2014
Externally publishedYes

Keywords

  • Clinical response
  • HLA-C binding KIR2D reports
  • IPH2101
  • KIR2D blockade
  • NK-cell function
  • Smoldering multiple myeloma

Fingerprint

Dive into the research topics of 'A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma'. Together they form a unique fingerprint.

Cite this